Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca’s “Smart Risks” Include Sharing FibroGen’s Anemia Compound With Astellas

This article was originally published in The Pink Sheet Daily

Executive Summary

The British pharma continues to build its cardiovascular and metabolic pipeline to slow its dive off the patent cliff; in FibroGen’s FG-4592, it sees a potential strong seller in regions where the privately held biotech's other pharma partner, Astellas, doesn’t already own rights.

You may also be interested in...



Biopharma Dealmaking Quarterly Statistics, Q3 2013

Biopharma financing in Q3 2013 totaled $4.6 billion, a 58% drop from the second quarter; Perrigo’s $8.3 billion acquisition of Elan made up more than half of the M&A dollar value; and marketed products made up the majority of licensed products.

Deals Of The Week: Wondering Where Have The Private Biotech Take-Outs Gone?

M&A has slowed for private biotechs this year, as acquisitions are overshadowed by IPOs. AstraZeneca is one of the few big biopharmas actively buying private biotechs. An option-to-acquire deal structure, amply employed by Celgene, is popping up lately.

AZ Builds Cardiac Regeneration, Diabetes R&D At Swedish Research Hub

Diabetic nephropathy, pancreatic islet cell health as well as heart failure will feature in early-stage research conducted by AstraZeneca's cardiometabolic iMED based in Mölndal, Sweden - now one of three strategic R&D centers for the trimmed-down British drug maker.

Related Content

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

PS076060

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel